Hims & Hers Health, Inc. saw its share prices increase by 9.24% to $36.16 as investors repositioned their portfolios ahead of the company's upcoming earnings report. The stock's rise reflects positive investor sentiment, likely fueled by the company's recent partnership with Novo Nordisk to market the weight loss drug Wegovy, which enhances its service offerings and market presence.

The partnership with Novo Nordisk allows Hims & Hers to provide direct access to Wegovy through its platform, bundling it with membership services that include ongoing clinical support. This strategic move not only diversifies Hims & Hers' product offerings but also positions the company favorably in the growing telehealth and weight management sectors, potentially driving future revenue growth.